Nesiritide
Nesiritide is a sterile, purified recombinant human B-type natriuretic peptide (hBNP) obtained from Escherichia coli. It facilitates cardiovascular homeostasis by binding to particulate guanylyl cyclase receptors in vascular smooth muscle and endothelial cells, leading to increased cGMP, smooth muscle relaxation, and vasodilation (both venous and arterial).
Dosage by Body Weight
Administered exclusively via the intravenous route under strict clinical monitoring. The standard adult dose begins with an IV bolus of 2 mcg/kg, followed immediately by a continuous IV infusion of 0.01 mcg/kg/min. Do not initiate at a higher dose.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- IV Bolus: 10 to 14 mcg, followed by continuous infusion of 0.05 to 0.07 mcg/min
- Frequency
- Continuous intravenous infusion
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Dosing is theoretically calculated based on the standard adult weight-based protocol (2 mcg/kg bolus, 0.01 mcg/kg/min infusion).
- Body Weight
- 8-10 kg
- Dose
- IV Bolus: 16 to 20 mcg, followed by continuous infusion of 0.08 to 0.10 mcg/min
- Frequency
- Continuous intravenous infusion
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Dosing is theoretically calculated based on the standard adult weight-based protocol.
- Body Weight
- 11-15 kg
- Dose
- IV Bolus: 22 to 30 mcg, followed by continuous infusion of 0.11 to 0.15 mcg/min
- Frequency
- Continuous intravenous infusion
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Dosing is theoretically calculated based on the standard adult weight-based protocol.
- Body Weight
- 16-20 kg
- Dose
- IV Bolus: 32 to 40 mcg, followed by continuous infusion of 0.16 to 0.20 mcg/min
- Frequency
- Continuous intravenous infusion
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Dosing is theoretically calculated based on the standard adult weight-based protocol.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and efficacy in pediatric patients have not been established. |
| 5-7 kg | IV Bolus: 10 to 14 mcg, followed by continuous infusion of 0.05 to 0.07 mcg/min | Continuous intravenous infusion | Safety and efficacy in pediatric patients have not been established. Dosing is theoretically calculated based on the standard adult weight-based protocol (2 mcg/kg bolus, 0.01 mcg/kg/min infusion). |
| 8-10 kg | IV Bolus: 16 to 20 mcg, followed by continuous infusion of 0.08 to 0.10 mcg/min | Continuous intravenous infusion | Safety and efficacy in pediatric patients have not been established. Dosing is theoretically calculated based on the standard adult weight-based protocol. |
| 11-15 kg | IV Bolus: 22 to 30 mcg, followed by continuous infusion of 0.11 to 0.15 mcg/min | Continuous intravenous infusion | Safety and efficacy in pediatric patients have not been established. Dosing is theoretically calculated based on the standard adult weight-based protocol. |
| 16-20 kg | IV Bolus: 32 to 40 mcg, followed by continuous infusion of 0.16 to 0.20 mcg/min | Continuous intravenous infusion | Safety and efficacy in pediatric patients have not been established. Dosing is theoretically calculated based on the standard adult weight-based protocol. |
Formulation
Purpose
Used for the intravenous treatment of patients with acutely decompensated heart failure (ADHF) who have dyspnea at rest or with minimal activity.
Generic Name
NesiritideBranded Drug Names
Nesiritide is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.